Skip to main content
SpringerLink
Log in
Book cover

Immunosuppression under Trial pp 111–121Cite as

Can we minimize the long-term side effects of immunosuppressive drugs in pediatric patients?

  • Chapter

Part of the book series: Transplantation and Clinical Immunology ((TRAC,volume 31))

Abstract

Renal transplantation is the treatment of choice for end-stage renal disease in children, leading to substantial improvement in the quality of life. However, despite a significant improvement in short-term results, important long-term problems remain unsolved. Allograft half-life has only slightly improved in pediatric renal transplant recipients during the last decade due to the lack of effective treatment for chronic rejection, frequent recipient non-compliance, particularly in adolescence, and nephrotoxicity of the immunosuppressive calcineurin inhibitors cyclosporine A and tacrolimus. Therefore, a pediatric renal graft recipient is likely to need several retransplantations during his life. Furthermore, the immunosuppressive drugs used today have potentially serious side effects, including infection, nephrotoxicity and de novo malignancy. These topics are particularly relevant for children who are likely to receive immuno-suppressive therapy for several decades. The biological differences between an adult and a growing and developing pediatric transplant recipient also have to be taken into account. It is important, therefore, to develop immunosup-pressive protocols that are adjusted to the specific needs of a growing child.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Mason J. The pathophysiology of Sandimmune (cyclosporine) in man and animals. Pediatr. Nephrol. 1990; 4: 554–574.

    CAS  Google Scholar 

  2. Novick AC, Ho-Hsieh H, Steinmuller DS et al. Detrimental effect of cyclosporine on initial function of cadaver renal allografts following extended preservation: Results of randomized prospective trial. Transplantation. 1986; 42: 154–158.

    Article  PubMed  CAS  Google Scholar 

  3. Laine J, Holmberg C. Renal and adrenal mechanisms in cyclosporine induced hyperkalemia after renal transplantation. Eur. J. Clin. Invest. 1995; 25: 670–676.

    Article  PubMed  CAS  Google Scholar 

  4. Laine J, Holmberg C. Mechanisms of hyperuricemia renal transplanted children. Nephron. 1996; 74: 318–323.

    Article  PubMed  CAS  Google Scholar 

  5. Kahan BD. Drug therapy: cyclosporine. N. Engl. J. Med. 1989; 321: 1725–1738.

    Article  PubMed  CAS  Google Scholar 

  6. Cho WY, Terasaki PI, Graver B. Fifteen-year kidney graft survival. In: Terasaki PI (ed.) Clinical Transplants. Los Angeles: UCLA Tissue Typing Laboratory: 1989; 325–331.

    Google Scholar 

  7. Myers BD, Newton L. Cyclosporine-induced chronic nephropathy: an obliterative micro-vascular injury. J. Am. Soc. Nephrol. 1991; 2(2 Suppl 1): S45–S52.

    PubMed  CAS  Google Scholar 

  8. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet. 1994; 344: 423–428.

    Article  Google Scholar 

  9. The US Multicenter Liver FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N. Engl. J. Med. 1994; 331: 1110–1115.

    Article  Google Scholar 

  10. Porayko MK, Texton SC, Krom RA et al. Nephrotoxic effects of primary immunosuppression with FK 506 and cyclosporine regimens after liver transplantation. Mayo. Clin. Proc. 1994; 69: 105–111.

    PubMed  CAS  Google Scholar 

  11. Holman MJ, Gonwa TA, Cooper B et al. FK506-associated thrombotic thrombocytopenic purpura. Transplantation. 1993; 55: 205–206.

    Article  PubMed  CAS  Google Scholar 

  12. Ruggenenti P, Perico N, Mosconi L et al. Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. Kidney Int. 1993; 43: 706–711.

    Article  PubMed  CAS  Google Scholar 

  13. Hoppu K, Koskimies O, Holmberg C, Hirvisalo EL. Pharmacokinetically determined cyclosporin dosage in young children. Pediatr. Nephrol. 1991; 5: 1–4.

    CAS  Google Scholar 

  14. Tejani A, Sullivan EK. Higher maintenance cyclosporine dose decreases the risk of graft failure in North American children: a report of the North American Pediatric Renal Transplant Cooperative Study. J. Am. Soc. Nephrol. 1996; 7: 550–555.

    PubMed  CAS  Google Scholar 

  15. Chrysostomou A, Walker RG, Russ GR et al. Diltiazem in renal allograft recipients receiving cyclosporine. Transplantation. 1993; 55: 300–304.

    Article  PubMed  CAS  Google Scholar 

  16. Mourad G, Ribstein J, Mimran A. Converting-enzyme inhibitor versus calcium antagonist in cyclosporine-treated renal transplants. Kidney Int. 1993; 43: 419–425.

    Article  PubMed  CAS  Google Scholar 

  17. Houde I, Noel R, Cotret PR et al. Prednisone-mycophenolate mofetil double therapy for cyclosporine A toxicity in kidney transplantation. Transplantation. 1998; Suppl 139: abstract 243.

    Google Scholar 

  18. Ducloux D, Fournier V, Bresson-Vautrin C et al. Mycophenolate mofetil in renal transplant recipients with cyclosporine-associated nephrotoxicity. Transplantation. 1998; 65: 1504–1506.

    Article  PubMed  CAS  Google Scholar 

  19. Sheil A. Cancer in dialysis and transplant patients. In: Morris P (ed.) Kidney Transplantation: Principles and Practice, 4th edn. Philadelphia: WB Saunders; 1994: 390–400.

    Google Scholar 

  20. Penn I. The problem of cancer in organ transplant recipients: an overview. Transplant. Sci. 1994; 4: 23–32.

    PubMed  CAS  Google Scholar 

  21. Penn I. The changing patterns of posttransplant malignancies. Transplant. Proc. 1991; 23: 1101–1103.

    PubMed  CAS  Google Scholar 

  22. Penn I. Cancers complicating organ transplantation. N. Engl. J. Med. 1990; 323: 1767–1769.

    Article  PubMed  CAS  Google Scholar 

  23. McEnery P, Stablein P, Arbus G, Tejani A. Renal transplantation in children. A report of the North American Pediatric Renal transplant Cooperative Study. N. Engl. J. Med. 1992; 326: 1727–1732.

    Article  PubMed  CAS  Google Scholar 

  24. Tejani A, Sullivan EK, Alexander S, Fine R, Harmon W, Lilienfeld D. Post-transplant deaths and factors that influence the mortality rate in North American children. Transplantation. 1994; 57: 547–553.

    PubMed  CAS  Google Scholar 

  25. Mullen DL, Silberg SG, Penn I, Hammond WS. Squamous cell carcinoma of the skin and lip in renal homograft recipients. Cancer. 1976; 37: 729–734.

    Article  PubMed  CAS  Google Scholar 

  26. Dantal J, Hourmant M, Cantarovich D et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet. 1998; 351: 623–628.

    Article  PubMed  CAS  Google Scholar 

  27. Ho M, Jaffe R, Miller G et al. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestation in children. Transplantation. 1988; 45: 719–724.

    Article  PubMed  CAS  Google Scholar 

  28. Opelz G, Henderson R, for the Collaborative Transplant Study. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet. 1993; 342: 1514–1516.

    Article  PubMed  CAS  Google Scholar 

  29. Conlon PJ, Smith SR. Transmission of cancer with cadaveric donor organs. J. Am. Soc. Nephrol. 1995; 6: 54–60.

    PubMed  CAS  Google Scholar 

  30. Gupta AK, Cardella CJ, Haberman HE Cutaneous malignant neoplasms in patients with renal transplants. Arch. Dermatol. 1986; 122: 1288–1293.

    Article  PubMed  CAS  Google Scholar 

  31. Halmos O, Inturri P, Galligioni A et al. Two cases of Kaposi’s sarcoma in renal and live transplant recipients treated with interferon. Clin. Transplant. 1996; 10: 374–378.

    PubMed  CAS  Google Scholar 

  32. Tönshoff B, Mehls O. Interactions between glucocorticoids and the growth hormone - insulin-like growth factor axis. Pediatr. Transplant. 1997; 1: 183–188.

    PubMed  Google Scholar 

  33. Tönshoff B, Mehls O. Factors affecting growth and strategies for treatment in children after renal transplantation. Pediatr. Transplant. 1997; 1: 176–182.

    PubMed  Google Scholar 

  34. Tejani AH, Fine RN, Alexander S et al. Factors predictive of sustained growth in children after renal transplantation. J. Pediatr. 1993; 122: 397–402.

    Article  PubMed  CAS  Google Scholar 

  35. Hokken-Koelega ACS, van Zaal AE, de Ridder MAJ et al. Growth after renal transplantation in prepubertal children: impact of various treatment modalities. Pediatr. Res. 1994; 3: 367–371.

    Article  Google Scholar 

  36. Broyer M, Guest G, Gagnadoux M-E Growth rate in children receiving alternate-day cortico steroid treatment after kidney transplantation. J. Pediatr. 1992; 120: 721–725.

    Article  PubMed  CAS  Google Scholar 

  37. Jabs K, Sullivan EK, Avner ED, Harmon WE. Alternate-day steroid dosing improves growth without adversely affecting graft survival or long-term graft function. Transplantation. 1996; 61: 31–36.

    Article  PubMed  CAS  Google Scholar 

  38. Klare B, Strom TM, Hahn H et al. Remarkable long-term prognosis and excellent growth in kidney-transplant children under cyclosporine monotherapy. Transplant. Proc. 1991; 23: 1013–1017.

    PubMed  CAS  Google Scholar 

  39. Ingulli E, Tejani AH. Steroid withdrawal after renal transplantation. In: Tejani AH, Fine RN (eds). Pediatric Renal Transplantation. New York: Wiley Liss, 1994; 221–238.

    Google Scholar 

  40. Shapiro R, Scantlebury VP, Jordan ML et al. FK 506 in pediatric kidney transplantation-Primary and rescue experience. Pediatr. Nephrol. 1995; 9: 43–48.

    Article  Google Scholar 

  41. Grinyo JM, Gil-Vernet S, Seron D et al. Steroid withdrawal in mycophenolate mofetil-treated renal allograft recipients. Transplantation. 1997; 63: 1688–1690.

    Article  PubMed  CAS  Google Scholar 

  42. Tönshoff B, Mehls O. Use of rhGH post transplant in children. In: Tejani AH, Fine RN (eds). Pediatric Renal Transplantation. New York: Wiley & Sons, 1994; 441–460.

    Google Scholar 

  43. Tönshoff B, Haffner D, Mehls O et al. Efficacy and safety of growth hormone treatment in short children with renal allografts: three year experience. Kidney. Int. 1993; 44: 199–207.

    Article  PubMed  Google Scholar 

  44. Guest G, Berard E, Crosnier H, Chevallier T, Rappaport R, Broyer M. Effects of growth hormone in short children after renal transplantation. French Society of Pediatric Nephrology. Pediatr. Nephrol. 1998; 12: 437–446.

    Article  PubMed  CAS  Google Scholar 

  45. Tönshoff B. Editorial: The current status of mycophenolate mofetil in pediatric renal transplantation. Pediatr. Transplant. 1999, in press.

    Google Scholar 

Download references

Authors
  1. B. Tönshoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. O. Mehls
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. Weber
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

P. Cochat J. Traeger C. Merieux M. Derchavane

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Tönshoff, B., Mehls, O., Weber, L. (1999). Can we minimize the long-term side effects of immunosuppressive drugs in pediatric patients?. In: Cochat, P., Traeger, J., Merieux, C., Derchavane, M. (eds) Immunosuppression under Trial. Transplantation and Clinical Immunology, vol 31. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-4643-2_14

Download citation

  • DOI: https://doi.org/10.1007/978-94-011-4643-2_14

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-5960-2

  • Online ISBN: 978-94-011-4643-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation